FDA Grants Breakthrough Therapy Designation for BioMarin’s Valoctocogene Roxaparvovec
BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formerly BMN 270) Breakthrough Therapy Designation. The FDA's…
Read More...
Read More...
